Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

In this article

India’s Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion, including debt.

The Indian generic drugmaker will acquire all outstanding shares of Organon

for $14 apiece, according to an exchange filing Monday by Sun Pharmaceutical

“Following a comprehensive review of strategic alternatives, our Board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders,” said Carrie Cox, executive chair at Organon, in the joint statement.